Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer

Efficacy of EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, to treat human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR is not persistent due to drug resistance. Reprogramming in energy (especially glucose) metabolism plays an important role in developme...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Cancer
Autores principales: Ye, Mingtong, Wang, Sufan, Wan, Ting, Jiang, Rui, Qiu, Yun, Pei, Lei, Pang, Nengzhi, Huang, Yuanling, Huang, Yufeng, Zhang, Zhenfeng, Yang, Lili
Formato: Artigo
Lenguaje:Inglês
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5688931/
https://ncbi.nlm.nih.gov/pubmed/29151965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.21035
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares